Angiotensin II antagonists: a new class of antihypertensive agent

Details

Serval ID
serval:BIB_46740D363DC8
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Angiotensin II antagonists: a new class of antihypertensive agent
Journal
British Journal of Clinical Practice
Author(s)
Waeber B., Brunner  H. R.
ISSN
0007-0947
Publication state
Published
Issued date
1996
Peer-reviewed
Oui
Volume
50
Number
5
Pages
265-8
Language
english
Notes
Journal Article
Review
Abstract
Losartan is an orally active angiotensin II antangonist that selectively blocks effects mediated by the stimulation of the AT1 subtype of the angiotensin II receptor. This agent, at doses of 50-150mg/day, is as effective at lowering blood pressure as chronic angiotensin converting enzyme (ACE) inhibitors. Losartan is generally well tolerated and has an incidence of adverse effects very similar, in double-blind controlled trials, to that of placebo. It does not cause coughing, the most common side-effect of the ACE inhibitors, most probably because angiotensin II antagonism has no impact on ACE, an enzyme known to process bradykinin and other cough-inducing peptides. Losartan is a promising antihypertensive agent with the potential to become a first-line option for the treatment of patients with high blood pressure.
Keywords
Antihypertensive Agents/pharmacokinetics/*pharmacologyBiphenyl Compounds/pharmacokinetics/*pharmacologyHumansImidazoles/pharmacokinetics/*pharmacologyLosartanReceptors, Angiotensin/*antagonists & inhibitorsTetrazoles/pharmacokinetics/*pharmacology
Pubmed
Web of science
Create date
06/03/2009 12:00
Last modification date
20/08/2019 13:51
Usage data